Genmab And Merck Ramp Up ADC Competition In Ovarian Cancer

 
• By Andrew McConaghie

Genmab is the latest company to join an escalating arms race in antibody-drug conjugates, challenging AbbVie’s lead in ovarian cancer treatment.

Ovarian cancer
• Source: Shutterstock

More from Business

More from Scrip